Boswellia and gut
What 2 graded rows on boswellia agree on for gut, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Boswellia page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Boswellia page, with its PubMed record.
Your question
Boswellia and gut
2 rows · 97 peopleSplit. 1 row found no difference and 1 had mixed results.
- DGrade D× 2
- Rows
- 2
- Trials
- 2
- People
- 97
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 66 people (2011) and found no difference.
The rows run from 31 to 66 people, published from 2007 to 2011: 2 single studies.
The rows
1 no difference · 1 mixed- DGrade DKeeping Crohn's disease in remission · No difference
RCT · n 66 · 2011 · Adults with Crohn's disease in remission (22 German centres); 82 randomised, 66 analysed for efficacy
2,400 mg/day (2 × 400 mg capsules three times daily) · 52 weeks (stopped early)
Remission was maintained in 59.9% on boswellia and 55.3% on placebo (P = 0.85); time to relapse, disease activity and quality of life did not differ, and tolerability matched placebo.
- DGrade DRemission of collagenous colitis (chronic watery diarrhea) · Mixed
RCT · n 31 · 2007 · Adults with chronic diarrhea and biopsy-proven collagenous colitis (Germany)
400 mg three times daily · 6 weeks
Clinical remission was 63.6% vs 26.7% on placebo per protocol (p = 0.04) but 43.8% vs 26.7% by intention to treat (p = 0.25); histology and quality of life did not change.